Defects in lymphocyte subsets and serological memory persist a median of 10 years after high-dose therapy and autologous progenitor cell rescue for malignant lymphoma
Defects in lymphocyte subsets and serological memory persist a median of 10 years after high-dose therapy and autologous progenitor cell rescue for malignant lymphoma
The number of survivors having undergone high-dose therapy (HDT) followed by auto-SCT continues to increase, although some of the long-term sequelae remain incompletely understood. The immunological status and quality of life of 37 HDT/auto-SCT survivors with lymphoma in continuous remission of ?3 years were assessed alongside 14 age-matched controls. At a median follow-up of 10.5 years (range 2.2-20.2) following HDT/auto-SCT, the proportion of CD4(+) cells remained significantly reduced in patients compared with controls (median 43.4% vs 62.5%, respectively; P=<0.001), predominantly a result of sustained reduction in the naive CD4(+) component (P<0.001). Naive CD8(+) lymphocytes (P=0.014) and transitional B cells (P=0.008) were also significantly reduced, but differences in other lymphocyte subsets were not observed. Uptake of revaccination following HDT/auto-SCT was sporadic; between 11% and 33% of patients had serological titres outside the protective ranges for five of six routinely used vaccines. In the main, patients were found to have a good quality of life, although their EORTC QLQ-C30 questionnaire scores were significantly lower for the physical and social functioning domains compared with controls. Ten years after HDT/auto-SCT immunological deficits persist; to avoid excess risk of preventable disease, serological immunity should be assessed post HDT/auto-SCT followed by appropriate revaccination.Bone Marrow Transplantation advance online publication, 14 May 2012; doi:10.1038/bmt.2012.73.
auto-SCT, long term, immune reconstitution, immunity, lymphoma, quality of life
1545–1551
Dean, H.F.
ee78acf3-2344-4e21-8b34-02b2e9b18f34
Cazaly, A.
f9b61bc5-e4ec-483a-8115-eb2235b3b703
Hurlock, C.
6cfab616-4710-488e-aab9-81685c301770
Borras, J.
7dc75f77-a0fd-4566-890d-c45086f894d6
Williams, A.P.
8efc1c43-4250-47d9-ad40-640d4c147b29
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
14 May 2012
Dean, H.F.
ee78acf3-2344-4e21-8b34-02b2e9b18f34
Cazaly, A.
f9b61bc5-e4ec-483a-8115-eb2235b3b703
Hurlock, C.
6cfab616-4710-488e-aab9-81685c301770
Borras, J.
7dc75f77-a0fd-4566-890d-c45086f894d6
Williams, A.P.
8efc1c43-4250-47d9-ad40-640d4c147b29
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Dean, H.F., Cazaly, A., Hurlock, C., Borras, J., Williams, A.P., Johnson, Peter W.M. and Davies, A.J.
(2012)
Defects in lymphocyte subsets and serological memory persist a median of 10 years after high-dose therapy and autologous progenitor cell rescue for malignant lymphoma.
Bone Marrow Transplantation, 47 (12), .
(doi:10.1038/bmt.2012.73).
(PMID:22580768)
Abstract
The number of survivors having undergone high-dose therapy (HDT) followed by auto-SCT continues to increase, although some of the long-term sequelae remain incompletely understood. The immunological status and quality of life of 37 HDT/auto-SCT survivors with lymphoma in continuous remission of ?3 years were assessed alongside 14 age-matched controls. At a median follow-up of 10.5 years (range 2.2-20.2) following HDT/auto-SCT, the proportion of CD4(+) cells remained significantly reduced in patients compared with controls (median 43.4% vs 62.5%, respectively; P=<0.001), predominantly a result of sustained reduction in the naive CD4(+) component (P<0.001). Naive CD8(+) lymphocytes (P=0.014) and transitional B cells (P=0.008) were also significantly reduced, but differences in other lymphocyte subsets were not observed. Uptake of revaccination following HDT/auto-SCT was sporadic; between 11% and 33% of patients had serological titres outside the protective ranges for five of six routinely used vaccines. In the main, patients were found to have a good quality of life, although their EORTC QLQ-C30 questionnaire scores were significantly lower for the physical and social functioning domains compared with controls. Ten years after HDT/auto-SCT immunological deficits persist; to avoid excess risk of preventable disease, serological immunity should be assessed post HDT/auto-SCT followed by appropriate revaccination.Bone Marrow Transplantation advance online publication, 14 May 2012; doi:10.1038/bmt.2012.73.
This record has no associated files available for download.
More information
Published date: 14 May 2012
Keywords:
auto-SCT, long term, immune reconstitution, immunity, lymphoma, quality of life
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 340836
URI: http://eprints.soton.ac.uk/id/eprint/340836
ISSN: 0268-3369
PURE UUID: aa898390-127e-4175-81e0-5a5576c655ae
Catalogue record
Date deposited: 03 Jul 2012 15:42
Last modified: 15 Mar 2024 03:31
Export record
Altmetrics
Contributors
Author:
H.F. Dean
Author:
A. Cazaly
Author:
C. Hurlock
Author:
J. Borras
Author:
A.P. Williams
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics